University of California San Francisco

Nola Hylton, PhD

Nola Hylton, PhD
Nola Hylton, PhD

Professor, School of Medicine, Radiology

Address

550 16th Street
San Francisco, CA 94158
United States

Email: [email protected]

ORCID: 0000-0002-6747-1662

Awards & Honors

Award Conferred By Date
Distinguished Investigator Academy of Radiology Research 2013
Cure Scholar Award Komen 2010
Scientific Advisory Council Susan G. Komen for the Cure's 2010
Research Scholar American Cancer Society 2003
Outstanding Contribution Award American College of Radiology Imaging Network 2003
Editor's Recognition Award with Distinction Radiology 1987/1988
Graduate Professional Opportunities Program Fellowship Stanford University 1979
Undergraduate Fellowship Bell Telephone Laboratories 1975

Grants and Funding

  • Real-time In Vivo MRI Biomarkers for Breast Cancer Pre-Operative Treatment Trials | NIH | 2008-04-25 - 2021-06-30 | Role: Principal Investigator
  • Quantitative Imaging for Assessing Breast Cancer Response to Treatment | NIH | 2011-09-26 - 2016-08-31 | Role: Principal Investigator
  • MRI For Staging DCIS and Assessing Response to Treatment | NIH | 2006-08-23 - 2013-07-31 | Role: Principal Investigator
  • NMR Imaging and Spectroscopy | NIH | 1993-06-01 - 2013-05-31 | Role: Co-Investigator
  • Anatomic and Biologic Staging of Breast Disease with MRI | NIH | 1997-01-15 - 2012-02-28 | Role: Principal Investigator
  • Mechanism-Based Evaluations of ErbB-Targeted Agents | NIH | 2001-09-26 - 2008-12-31 | Role: Co-Investigator

Publications

MOST RECENT PUBLICATIONS FROM A TOTAL OF 10
  1. Automated Apparent Diffusion Coefficient Measurement of Breast Tumors in Diffusion-weighted MRI for Early Neoadjuvant Chemotherapy Response Assessment.
    Le NN, Li W, Wilmes LJ, Onishi N, Gibbs JE, Hathi D, Metanat P, Joe BN, Kornak J, Malyarenko D, Chenevert TL, Bolan P, Partridge SC, Hylton NM| | PubMed
  2. Comparative 10-year performance of mammography artificial intelligence, polygenic, and clinical breast cancer risk models in the Kaiser Permanente Research Bank.
    Arasu VA, Gadgil T, Rothstein JH, Alexeeff SE, Achacoso NS, Bhattacharya A, Cord JB, Esserman LJ, Galbraith W, Gerstley LD, Head ST, Hylton NM, Kushi LH, Lee C, Leimpeter AD, Lewis DA, Liu V, Marafino BJ, Margolies LR, Navarro DA, Pu A, Sakoda LC, Shan J, Shieh Y, Sistig A, Smith Gueye CL, Veer LV, Villaseñor M, Westley M, Wisner DJ, Tice JA, Shen L, Habel LA, Sieh W| | PubMed
  3. Image Quality Assessment of Diffusion-Weighted Imaging (DWI) and Its Impact on Apparent Diffusion Coefficient (ADC) as a Quantitative Imaging Biomarker for Predicting Response to Neoadjuvant Chemotherapy in High-Risk Early Breast Cancer.
    Li W, Wilmes LJ, Carmona-Bozo J, Le NN, Chung M, Gibbs JE, Onishi N, Price E, Joe BN, Kornak J, Chenevert TL, Malyarenko D, Bolan PJ, Partridge SC, Hylton NM| | PubMed
  4. The Future of Quantitative Breast Imaging: Integrated to Integral Imaging Biomarkers for Precision Cancer Care, From the AJR Special Series on Quantitative Imaging.
    McDonald ES, Kazerouni AS, Metanet P, Barinov L, Partridge SC, Hylton NM| | PubMed
  5. A prospective single-arm pilot study evaluating [F-18]fluoroestradiol dedicated breast PET in invasive lobular carcinoma after neoadjuvant endocrine therapy.
    Switalla KM, Onishi N, Jones EF, Lawhn-Heath C, Ray KM, Hathi DK, Carmona-Bozo JC, Metanat P, Lopes AJ, Falade IO, Quirarte A, Gottipati S, Guo R, Molina-Vega J, Pullakhandam K, Bareng TJ, Watkins M, Chien AJ, Joe BN, Esserman LJ, Hylton N, Mukhtar RA| | PubMed
  6. Hormone signaling and immune programs define differential endocrine responsiveness in high-risk breast tissue.
    Goldhammer N, Bont M, Warhadpande S, Choi M, Cedano J, Greenwood H, Ye J, Schwartz CJ, Alvarado M, Ewing C, Goodwin K, Mukhtar RA, Wong J, Abe SE, Chandler J, Jackson J, Olopade OI, Campbell MJ, Lam A, Park C, Vertido A, van 't Veer LJ, Hylton N, Esserman LJ, Rosenbluth JM| | PubMed
  7. Identification of Early Symptoms Associated with Subsequent Immune-related Adverse Events in the I-SPY clinical trial.
    Basu A, Umashankar S, Melisko M, Roy R, Yau C, Pusztai L, Chien AJ, Liu M, Han H, Soliman H, Isaacs C, Shatsky R, Stringer-Reasor E, Robinson P, Yeung K, Kalinsky K, Thomas A, Philip E, Musthafa M, Hirst G, Asare A, DeMichele A, Van't Veer L, Yee D, Hylton N, Olshen A, Perlmutter J, Cohen RN, Quandt Z, Esserman L, Hershman D, Rugo H, Nanda R| | PubMed
  8. RISE UP for breast cancer 2024: conference highlights & takeaways.
    Glatt T, Leggat-Barr K, Seth N, Heditsian D, van 't Veer L, Pusztai L, Price E, Hylton N, Formenti S, Rugo H, Fejerman L, Toriola AT, Fabian C, De Censi A, Grossman D, Olopade O, Jackson A, Horton S, Rhoads K, Lange C, Borges V, Garner E, Garber J, Yee D, Esserman L| | PubMed
  9. CHFR expression and sensitivity of breast cancer cells to antimitotic agents in vitro and in the I-SPY trial.
    Wahner Hendrickson AE, Flatten KS, Weiskittel TM, Venkatachalam A, Strathman AR, Rossman OK, Meng XW, Schneider PA, Peterson KL, Correia C, Anderson OJ, Singh S, Couch FJ, Esserman LJ, Hylton NM, Onishi N, DeMichele AM, Chen J, Li H, Ingle JN, Goetz MP, Kaufmann SH| | PubMed
  10. Impact of Time to Surgery Post Neoadjuvant Chemotherapy on Breast Cancer Outcomes: A Retrospective Study of Patients Enrolled in the I-SPY 2 Clinical Trial.
    Van Hassel J, Dimitroff K, Yau C, Mukhtar R, Boughey JC, Ladores V, Howard-McNatt MM, Jaskowiak N, Perlmutter J, DeMichele A, Yee D, Hylton N, Symmans WF, Veer LV, Rugo H, Esserman LJ, Shatsky R, Isaacs C, Kuerer H, Wallace AM, Prionas N, Tseng J, Reyna CR, Taunk N, Kesmodel S, Lee MC, Fox J, Piltin MA, Tchou J, Arciero CA, Postlewait LM, Sauder C, Rao R| | PubMed